JPMorgan analyst Casey Woodring upgraded Sotera Health to Neutral from Underweight with a price target of $18, up from $6, following the legal settlement of all the company’s Illinois cases. The cases served as the key overhang on the stock, the analyst tells investors in a research note. However, the firm still sees headwinds for Sotera related to Nelson Lab testing softness and heightened Nordion "lumpiness" next year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on SHC:
- Sotera Health upgraded to Outperform at Wolfe Research after Illinois settlement
- Sotera Health upgraded to Outperform from Peer Perform at Wolfe Research
- Sotera Health double-upgraded to Overweight from Underweight at Barclays
- Sotera Health ‘to rock’ with ‘massive overhang’ removed, says Wolfe Research
- Here’s What Caused Sotera Health’s (NASDAQ:SHC) Stunning Rally